ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Alexion, a rare disease–focused group within AstraZeneca, will acquire the genomic medicine company LogicBio Therapeutics. Alexion says it is interested in LogicBio’s technology for delivering and inserting genes using adeno-associated viruses to address rare genetic diseases. Alexion is paying $2.07 per share, or about $70 million—well over LogicBio’s share price of less than 50 cents before the deal was announced.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter